Loading stock data…
BCAX
$20.99-1.39 (-6.21%)
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bicara Therapeutics Inc. in the Healthcare sector is trading at $20.99. Wall Street consensus targets $31.46 (13 analysts), implying a +49.9% move over the next 12 months. The stock is currently near its 52-week high of $24.25, remaining 26.0% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +49.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$20.99
Potential Downside
0%
Whystock Fair Value$20.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$31.46+49.9%
Range$16.00 – $46.00
Fundamentals
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal g...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.36%
Volume
Today's trading volume
1.29M
Recent News
Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
Bicara Therapeutics Inc (BCAX) reports robust cash reserves and strategic progress in its Fortify HN01 trial, positioning Fisera for potential accelerated approval.
Bicara Therapeutics Inc. Common Stock Q1 2026 Earnings Call Summary
Moby summary of Bicara Therapeutics Inc. Common Stock's Q1 2026 earnings call
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering. On the company’s fir
Biocon's Mazumdar-Shaw sets out 5-year succession plan, names niece Claire as successor
By Rishika Sadam May 5 (Reuters) - Biocon founder and chairperson Kiran Mazumdar-Shaw plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to take
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.